IRVINE, Calif., March 21, 2024 /PRNewswire/ -- Allergan Aesthetics demonstrates its ongoing commitment to originality and its bold approach to aesthetics at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Wednesday, March 27– Friday, March 29, 2024. Events include two Allergan Medical Institute (AMI) symposia, Science of AgingTM event, Meet the Expert presentations, poster sessions and an interactive exhibition booth.
"AMWC presents an invaluable opportunity to meet with esteemed experts from across the globe," said Carrie Strom, President, Global Allergan Aesthetics. "Through our expert-led AMI symposia and series of thought-provoking events, we're showcasing our innovative approach to aesthetics with an emphasis on thoughtful consultation with our diverse and expanding product portfolio to further shape the future of the industry."
As industry pioneers, Allergan Aesthetics has been at the forefront of uncovering the trends that are shaping aesthetics. Activities taking place at AMWC this year further showcase Allergan Aesthetics timeless approach as it goes beyond the trends with decisive and thoughtful action. Centering around its True Originals theme, Individuality, Innovation and Integrity, Allergan Aesthetics is shaping the future of the aesthetics industry.
AMWC 2024 AMI symposia
The first symposium, 'True Originals: A Personalised Approach with the Allergan Aesthetics Range', focuses on an in-depth look into patient needs. The symposium will be co-chaired by Dr. Sophie Shotter (UK) and cosmetic dermatologist Dr. Andre Braz (Brazil), with expert panel discussions and two live injector sessions from Dr. Mansi Mukherjee (UAE) and Dr. Steven Liew (Australia).
The second day opens with an introduction to the future of individuality from Carrie Strom, President, Global Allergan Aesthetics, Dr. Tapan Patel (UK) and Dr. Juliana Chieppe (Brazil) and leads to the symposium 'True Originals: Decoding the Future of Aesthetic Individuality'. During the session, they will dive deeper into the exclusive report and discuss trends, techniques, and drivers for personalized treatment around the world. To end the day, renowned plastic surgeon Dr. Mauricio de Maio (Brazil) will perform a live injection on stage.
The symposia will take place as follows:
Beyond the AMI symposia
Dr. Steven Dayan will chair the Global Aesthetics Medical Affairs symposia, presenting 'Socially Transformative Aesthetic Medicine' alongside Dr. Mitchell Brin (US), Dr. Izolda Heydenrych (South Africa) and Damon Caiazza (US). Key topics include bias, emotional impact, social perception and future innovation.
Dr. Stephanie Manson Brown, Vice President, Head of Clinical Development and Scientific Innovation at Allergan Aesthetics, will open the exclusive thought-provoking Science of AgingTM symposia event, where world-class experts Dr Saranya Wyles (US), Professor Claire Stewart (UK), Professor Gordan Lauc (Croatia) and Dr Janine Sengstack (US) will present the latest early science and research insights in the field of aging. Key topics include cellular aging and rejuvenation, exosomes and glyconology. The session will conclude with a Q&A session led by event chair Dr. Patricia Ogilvie (Germany).
The symposia will take place as follows:
Meet the Experts
Allergan Aesthetics will host a series of Meet the Experts sessions live from the booth, featuring:
Aesthetics-Ethics
AMWC 2024 marks the launch of Moving the Needle on Ethics, a collaboration with medical aesthetics experts from around the globe with the aim of igniting thoughtful conversations on the importance of ethics in aesthetics medicine. This initiative is a result of Allergan Aesthetics' extensive global research on ethics, which includes global social media listening, insight gathering and face-to-face discussions across the industry in 13 countries.1
Visit the global Allergan Aesthetics website to download the 'Moving the Needle on Ethics' book and discover how Allergan Aesthetics is spotlighting future industry priorities in collaboration with leading experts. The 'Moving the Needle on Ethics' short film will be available to watch from the booth.
Allergan Aesthetics booth
Attendees can explore interactive areas of the booth K2 (Ravel Floor) to learn more about Allergan Aesthetics' commitment to maintaining its True Original status, and actions it's taking to empower excellence and lead innovation in aesthetics.
New clinical data on toxins and fillers
Allergan Aesthetics' commitment to advancing clinical data and evidence is demonstrated with the acceptance of 17 poster presentations to this year's congress. Posters have been accepted across various products, treatments and indications. For poster details please see Notes to Editors below.
Be a True Original with Allergan Aesthetics. Visit the symposia and exhibition booth K2, Ravel Floor in the Grimaldi Forum to discover more.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Notes to Editors
Please find titles and named authors for the 17 posters to be showcased at AMWC 2024 included below:
1 Allergan Aesthetics. Ethics social listening. October 2022 – REF-102346
Last Trade: | US$164.99 |
Daily Volume: | 0 |
Market Cap: | US$292.030B |
November 18, 2024 October 31, 2024 October 30, 2024 October 28, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB